MX2011007371A - Metodo para tratar la hiperglucemia con la molecula. - Google Patents

Metodo para tratar la hiperglucemia con la molecula.

Info

Publication number
MX2011007371A
MX2011007371A MX2011007371A MX2011007371A MX2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A
Authority
MX
Mexico
Prior art keywords
glp
treating hyperglycemia
diabetes
diketopiperazine
administered
Prior art date
Application number
MX2011007371A
Other languages
English (en)
Inventor
Peter Richardson
Donald Costello
Robert A Baughman
Mark T Marino
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MX2011007371A publication Critical patent/MX2011007371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un método para tratar la hiperglucemia y/o diabetes en un sujeto. En particular, el método está dirigido a un tratamiento de pacientes con diabetes melitus tipo 2 quienes tienen una concentración de glucosa en la sangre en ayunas mayor de aproximadamente 8 mM, en donde el paciente es administrado con una formulación que comprende una molécula GLP-1 y una dicetopiperazina mediante inhalación pulmonar con un sistema de inhalación de polvo seco.
MX2011007371A 2009-01-08 2010-01-08 Metodo para tratar la hiperglucemia con la molecula. MX2011007371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14335809P 2009-01-08 2009-01-08
PCT/US2010/020448 WO2010080964A1 (en) 2009-01-08 2010-01-08 Method for treating hyperglycemia with glp-1

Publications (1)

Publication Number Publication Date
MX2011007371A true MX2011007371A (es) 2011-09-06

Family

ID=41820660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007371A MX2011007371A (es) 2009-01-08 2010-01-08 Metodo para tratar la hiperglucemia con la molecula.

Country Status (12)

Country Link
US (1) US9078866B2 (es)
EP (2) EP2379100B1 (es)
JP (2) JP5918539B2 (es)
AU (2) AU2010203573A1 (es)
CA (1) CA2749099A1 (es)
DK (1) DK2379100T3 (es)
ES (1) ES2529100T3 (es)
HK (1) HK1164112A1 (es)
MX (1) MX2011007371A (es)
PT (1) PT2379100E (es)
SI (1) SI2379100T1 (es)
WO (1) WO2010080964A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
BRPI0615819B8 (pt) 2005-09-14 2021-05-25 Mannkind Corp processo para preparar uma composição de distribuição de fármaco compreendendo um agente ativo e uma micropartícula fumaril dicetopiperazina cristalina.
CN101389348A (zh) 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
KR20130117755A (ko) 2010-06-21 2013-10-28 맨카인드 코포레이션 건조 분말 약물 운반 시스템 및 방법
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
EP2890391A4 (en) * 2012-08-29 2016-03-09 Mannkind Corp METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
JP6491658B2 (ja) 2013-07-18 2019-03-27 マンカインド コーポレイション 熱安定性乾燥粉末医薬組成物及び方法
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
DE202016104106U1 (de) 2015-08-07 2016-10-09 Hitachi Koki Co., Ltd. Elektrowerkzeug

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
CO5090908A1 (es) 1998-08-28 2001-10-30 Lilly Co Eli Procedimiento para administrar peptidos insulinotropicos
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
AU2353701A (en) 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
EP1257577B1 (en) 2000-01-27 2004-04-21 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (glp-1) compounds
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
EP1301187B1 (en) * 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
EP2186824A3 (en) 2000-12-13 2010-09-22 Eli Lilly & Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040121964A1 (en) 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2004080482A2 (en) * 2003-03-11 2004-09-23 Institut De Cardiologie De Montréal / Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
AU2005204378B2 (en) * 2004-01-12 2009-01-22 Mannkind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
US20050265927A1 (en) 2004-05-17 2005-12-01 Yale University Intranasal delivery of nucleic acid molecules
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
EP1827381A1 (en) 2004-12-03 2007-09-05 Mederio AG A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
SE0402976L (sv) 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
WO2006086107A2 (en) * 2005-01-10 2006-08-17 Mannkind Corporation Methods and compositions for minimizing accrual of inhalable insulin in the lungs
ES2439455T3 (es) * 2005-08-01 2014-01-23 Mannkind Corporation Procedimiento de preservar la función de las células productoras de insulina
BRPI0615819B8 (pt) 2005-09-14 2021-05-25 Mannkind Corp processo para preparar uma composição de distribuição de fármaco compreendendo um agente ativo e uma micropartícula fumaril dicetopiperazina cristalina.
CN101389348A (zh) 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
BRPI0709964A2 (pt) * 2006-04-14 2011-08-02 Mannkind Corp formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)
EP2214647A2 (en) 2007-10-24 2010-08-11 MannKind Corporation Delivery of active agents
EP2954893A1 (en) * 2007-10-24 2015-12-16 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes

Also Published As

Publication number Publication date
PT2379100E (pt) 2015-02-09
EP2379100A1 (en) 2011-10-26
US9078866B2 (en) 2015-07-14
HK1164112A1 (en) 2012-09-21
ES2529100T3 (es) 2015-02-16
AU2016200249A1 (en) 2016-02-04
JP2015157817A (ja) 2015-09-03
US20120094905A1 (en) 2012-04-19
EP2379100B1 (en) 2014-11-12
AU2010203573A1 (en) 2011-06-30
SI2379100T1 (sl) 2015-02-27
CA2749099A1 (en) 2010-07-15
WO2010080964A1 (en) 2010-07-15
JP5918539B2 (ja) 2016-05-18
DK2379100T3 (en) 2014-12-01
EP2853268A1 (en) 2015-04-01
JP2012514646A (ja) 2012-06-28

Similar Documents

Publication Publication Date Title
MX2011007371A (es) Metodo para tratar la hiperglucemia con la molecula.
MX2007012102A (es) Control superior de glucosa en la sangre en tratamiento de diabetes.
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
JP2013541576A5 (es)
PL2211842T3 (pl) Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym
WO2007139941A3 (en) Composition and methods for treatment of congestive heart failure
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
MY158627A (en) Halogen-stabilized insulin
WO2011020319A8 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
RU2012100397A (ru) Препарат, содержащий инсулин, никотинамид и аминокислоту
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
WO2008116822A3 (en) Device for the medical care of a patient in an emergency
RS52629B (en) LIXISENATIDE AS ADDITIONAL THERAPY INSULIN GLARGINE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT
MX2013011174A (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
Mafauzy et al. DiabCare 2013: A cross-sectional study of hospital based diabetes care delivery and prevention of diabetes related complications in Malaysia
Enginyurt et al. The role of pure honey in the treatment of diabetes mellitus
WO2007076505A3 (en) Transferrin and transferrin-based compositions for diabetes treatment
JP2011105610A5 (es)
Lepore et al. Age and A1C are important clinical predictors of continuous subcutaneous insulin infusion efficacy in type 1 diabetic patients
Min et al. Effect of short-term intensive therapy with glimepiride and metformin in newly diagnosed type 2 diabetic patients
WO2009057461A1 (ja) 糖尿病治療剤
Szatmári et al. Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia
CN103948544B (zh) 重组Exendin-4鼻腔喷雾剂及其制备方法
Kwon et al. PE040: Restoration of the first-phase insulin secretion and a decline in fat mass are predictors for achieving long-term glycemic control after early intensive insulin therapy in patients with newly diagnosed type 2 diabetes
Pertzov et al. Efficacy And Safety Of Laryngeal Mask Airway Assisted Bronchoscopy Versus Standard Nasal Bronchoscopy

Legal Events

Date Code Title Description
FG Grant or registration